サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1434094

急性骨髄性白血病治療薬市場：疾患タイプ、治療タイプ、流通チャネル別- 世界予測2024-2030年

Acute Myeloid Leukemia Therapeutics Market (AML) by Disease Type (Myeloblastic, Myelomonocytic, Promyelocytic), Treatment Type (Chemotherapy, Targeted Therapy), Distribution Channel - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 182 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
急性骨髄性白血病治療薬市場：疾患タイプ、治療タイプ、流通チャネル別- 世界予測2024-2030年
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

急性骨髄性白血病治療薬市場規模は2023年に9億2,182万米ドルと推定され、2024年には10億2,156万米ドルに達し、CAGR 11.94%で2030年には20億3,049万米ドルに達すると予測されます。

急性骨髄性白血病治療薬の世界市場

主な市場の統計
基準年[2023］ 9億2,182万米ドル
予測年 [2024] 10億2,156万米ドル
予想年【2030年 20億3,049万米ドル
CAGR（%） 11.94%
急性骨髄性白血病治療薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは急性骨髄性白血病治療薬市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、急性骨髄性白血病治療薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-急性骨髄性白血病治療薬市場の市場規模および予測は？

2-急性骨髄性白血病治療薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-急性骨髄性白血病治療薬市場における技術動向と規制の枠組みは？

4-急性骨髄性白血病治療薬市場における主要ベンダーの市場シェアは？

5-急性骨髄性白血病治療薬市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中での急性骨髄性白血病の有病率
      • がん治療の必要性の高まりに伴い、がん啓発プログラムを強化
      • 急性骨髄性白血病の治療を支援するための政府の好意的な取り組み
    • 抑制要因
      • 急性骨髄性白血病の治療費は高額
    • 機会
      • 新規急性骨髄性白血病治療法の開発
      • 急性骨髄性白血病治療薬の支持率の上昇
    • 課題
      • 骨髄性白血病の治療に伴う副作用
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 急性骨髄性白血病治療薬市場：疾患タイプ別

  • 骨髄芽球性
  • 骨髄単球性
  • 前骨髄球性

第7章 急性骨髄性白血病治療薬市場治療タイプ別

  • 化学療法
  • 標的療法

第8章 急性骨髄性白血病治療薬市場：流通チャネル別

  • 病院薬局
  • オンライン薬局
  • 小売薬局

第9章 南北アメリカの急性骨髄性白血病治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の急性骨髄性白血病治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの急性骨髄性白血病治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbbVie Inc.
    • Actinium Pharmaceuticals, Inc.
    • Agios Pharmaceuticals, Inc.
    • Amgen Inc.
    • Astellas Pharma Inc.
    • Astex Pharmaceuticals, Inc. by Otsuka Group
    • Celgene Corporation
    • CTI BioPharma Corp.
    • Cyclacel Pharmaceuticals, Inc.
    • Daiichi Sankyo Company, Limited
    • Eisai Co., Ltd.
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline plc
    • Janssen Global Services, LLC
    • Jazz Pharmaceuticals PLC
    • Johnson & Johnson Services, Inc.
    • MEI Pharma, Inc.
    • Merck & Co., Inc.
    • Merus N.V.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Sun Pharmaceutical Industries Ltd.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • The Bristol Myers Squibb Company
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 8. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 10. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 12. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MYELOBLASTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY MYELOMONOCYTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY PROMYELOCYTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 10. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 13. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. BRAZIL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. CANADA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. MEXICO ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. UNITED STATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. ASIA-PACIFIC ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AUSTRALIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDONESIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. JAPAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MALAYSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. PHILIPPINES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. SINGAPORE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SOUTH KOREA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. TAIWAN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. THAILAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. VIETNAM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. DENMARK ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. EGYPT ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. FINLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FRANCE ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. GERMANY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. ISRAEL ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ITALY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. NETHERLANDS ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NIGERIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NORWAY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. POLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. QATAR ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. RUSSIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SAUDI ARABIA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH AFRICA ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SPAIN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SWEDEN ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWITZERLAND ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TURKEY ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED ARAB EMIRATES ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED KINGDOM ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 143. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 144. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 145. ACUTE MYELOID LEUKEMIA THERAPEUTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-02026C4C8BB8

[182 Pages Report] The Acute Myeloid Leukemia Therapeutics Market size was estimated at USD 921.82 million in 2023 and expected to reach USD 1,021.56 million in 2024, at a CAGR 11.94% to reach USD 2,030.49 million by 2030.

Global Acute Myeloid Leukemia Therapeutics Market

KEY MARKET STATISTICS
Base Year [2023] USD 921.82 million
Estimated Year [2024] USD 1,021.56 million
Forecast Year [2030] USD 2,030.49 million
CAGR (%) 11.94%
Acute Myeloid Leukemia Therapeutics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Acute Myeloid Leukemia Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Acute Myeloid Leukemia Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Acute Myeloid Leukemia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Actinium Pharmaceuticals, Inc., Agios Pharmaceuticals, Inc., Amgen Inc., Astellas Pharma Inc., Astex Pharmaceuticals, Inc. by Otsuka Group, Celgene Corporation, CTI BioPharma Corp., Cyclacel Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Janssen Global Services, LLC, Jazz Pharmaceuticals PLC, Johnson & Johnson Services, Inc., MEI Pharma, Inc., Merck & Co., Inc., Merus N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and The Bristol Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Acute Myeloid Leukemia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Disease Type
    • Myeloblastic
    • Myelomonocytic
    • Promyelocytic
  • Treatment Type
    • Chemotherapy
    • Targeted Therapy
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Acute Myeloid Leukemia Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Acute Myeloid Leukemia Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Acute Myeloid Leukemia Therapeutics Market?

4. What is the market share of the leading vendors in the Acute Myeloid Leukemia Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Acute Myeloid Leukemia Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Acute Myeloid Leukemia Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of acute myeloid leukemia cases worldwide
      • 5.1.1.2. Increasing cancer awareness programs with growing need for cancer therapy
      • 5.1.1.3. Favorable government initiatives to support the acute myeloid leukemia therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of acute myeloid leukemia therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel acute myeloid leukemia treatments
      • 5.1.3.2. Rise in approval rate of acute myeloid leukemia therapeutics
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with the myeloid leukemia treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Acute Myeloid Leukemia Therapeutics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Myeloblastic
  • 6.3. Myelomonocytic
  • 6.4. Promyelocytic

7. Acute Myeloid Leukemia Therapeutics Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Targeted Therapy

8. Acute Myeloid Leukemia Therapeutics Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Online Pharmacy
  • 8.4. Retail Pharmacy

9. Americas Acute Myeloid Leukemia Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Acute Myeloid Leukemia Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Acute Myeloid Leukemia Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. AbbVie Inc.
    • 13.1.2. Actinium Pharmaceuticals, Inc.
    • 13.1.3. Agios Pharmaceuticals, Inc.
    • 13.1.4. Amgen Inc.
    • 13.1.5. Astellas Pharma Inc.
    • 13.1.6. Astex Pharmaceuticals, Inc. by Otsuka Group
    • 13.1.7. Celgene Corporation
    • 13.1.8. CTI BioPharma Corp.
    • 13.1.9. Cyclacel Pharmaceuticals, Inc.
    • 13.1.10. Daiichi Sankyo Company, Limited
    • 13.1.11. Eisai Co., Ltd.
    • 13.1.12. F. Hoffmann-La Roche AG
    • 13.1.13. GlaxoSmithKline plc
    • 13.1.14. Janssen Global Services, LLC
    • 13.1.15. Jazz Pharmaceuticals PLC
    • 13.1.16. Johnson & Johnson Services, Inc.
    • 13.1.17. MEI Pharma, Inc.
    • 13.1.18. Merck & Co., Inc.
    • 13.1.19. Merus N.V.
    • 13.1.20. Novartis AG
    • 13.1.21. Pfizer Inc.
    • 13.1.22. Sanofi S.A.
    • 13.1.23. Sun Pharmaceutical Industries Ltd.
    • 13.1.24. Takeda Pharmaceutical Company Limited
    • 13.1.25. Teva Pharmaceutical Industries Ltd.
    • 13.1.26. The Bristol Myers Squibb Company
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing